Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin + cyclophosphamide + levamisole
- Development stage
- Unknown
- Lead developer
- Baxter
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination chemotherapy regimen consisting of doxorubicin (adriamycin), cyclophosphamide, and levamisole. This regimen combines traditional cytotoxic chemotherapy (doxorubicin and cyclophosphamide) with immunomodulatory therapy (levamisole). It was studied primarily for breast cancer treatment in the 1980s, both in adjuvant settings for primary breast cancer and for metastatic disease.
- Other names
- adriamycin + cyclophosphamide + levamisoleFAC + levamisoleAC + levamisole
02
Targets
DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on doxorubicin + cyclophosphamide + levamisole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin + cyclophosphamide + levamisole.